Ziprasidone outcome and tolerability: A practical clinical trial with plasma drug levels

Pharmacopsychiatry

Volumn 40, Issue 3, 2007, Pages 89-92

  Mauri, M C ^a,c   Colasanti, A ^a   Rossattini, M ^a   Volonteri, L S ^a   Dragogna, F ^a   Fiorentini, A ^a   Valli, A ^b   Papa, P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Negative symptoms; Plasma levels; Schizophrenia; Second generation antipsychotics; Serum concentrations; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES;

EID: 34250344652     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-973835     Document Type: Article

References (22)

1. Allison D-B, Casey D-E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (S7): 22-31
2. Angermeyer M-C, Matschinger H. Attitude of family to neuroleptics. Psychiatr Prax 1999; 26: 171-174
3. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M et al. Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
4. Caley C-F, Cooper C-K. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36: 839-851
5. Daniel D-G, Zimbroff D-L, Potkin S-G, Reeves K-R, Harrigan E-P, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505
6. Glassman A-H, Bigger J-T Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782
7. Goff D-C, Posever T, Herz L, Simmons J, Kletti N, Lapierre K et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296-304
8. Gunasekara N-S, Spencer C-M, Keating G-M. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs 2002; 16: 6456-6452
9. Harrigan E-P, Miceli J-J, Anziano R, Watsky E, Reeves K-R, Cutler N-R. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62-69
10. Hugenholtz G-W, Heerdink E-R, Meijer W-E, Stolker J-J, Egberts A-C, Nolen W-A. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124
11. Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006; 39: 47-51
12. Kay S-R, Fiszbein A, Opler L-A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
13. Leuner K, Muller W-E. The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry 2006; 39: 15-20
14. Mamo D, Kapur S, Shammi C-M, Papatheodorou G, Mann S, Therrien F et al. PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161: 818-825
15. Mauri M-C, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001; 16: 57-63
16. Mauri M-C, Steinhilber C-P, Marino R, Invernizzi E, Fiorentini A, Cerveri G et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20: 55-60
17. Mauri M-C, Laini V, Cerveri G, Scalvini M-E, Volonteri L-S, Regispani F et al. Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 597-601
18. Pascual J-C, Madre M, Soler J, Barrachina J, Campins MJ, Alvarez E et al. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006; 39: 117-118
19. Percudani M, Barbui C, Fortino I, Petrovich L. Epidemiology of first- and second-generation antipsychotics agents in Lombardy, Italy. Pharmacopsychiatry 2005; 38: 128-131
20. Prior T-I, Chue P-S, Tibbo P, Baker G-B. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9: 301-309
21. Simpson G-M, Angus J-W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19
22. Weiden P-J, Daniel D-G, Simpson G, Romano S-J. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23: 595-600